#1 Clinical Trials Search in Europe

Tiragolumab

Tiragolumab is an innovative immunotherapy drug currently being studied in various clinical trials for different types of cancer. This article explores how tiragolumab, often combined with other immunotherapy drugs like atezolizumab, is being investigated as a potential treatment for cancers such as lung cancer, cervical cancer, and other solid tumors. We’ll look at the ongoing research, potential benefits, and what patients should know about this emerging therapy.

Table of Contents

Introduction

Tiragolumab is an exciting new immunotherapy drug that is currently being studied in clinical trials for treating various types of cancer. It works by helping activate the body’s own immune system to fight cancer cells. Tiragolumab is often used in combination with another immunotherapy drug called atezolizumab (also known by the brand name Tecentriq)[2].

How Tiragolumab Works

Tiragolumab is a type of drug called an anti-TIGIT antibody. It works by blocking a protein called TIGIT that is found on immune cells. By blocking TIGIT, tiragolumab helps activate immune cells to recognize and attack cancer cells more effectively[3].

When used in combination with atezolizumab, which blocks a different immune checkpoint protein called PD-L1, the two drugs work together to boost the immune response against cancer from multiple angles[2].

Conditions Treated

Tiragolumab is being studied for treating several types of cancer, including:

  • Non-small cell lung cancer (NSCLC) – A common type of lung cancer[2][3]
  • Esophageal squamous cell carcinoma – A type of cancer affecting the esophagus[1]
  • Cervical cancer – Cancer of the cervix[5]
  • Other solid tumors with certain genetic features[4]

Current Clinical Trials

Several clinical trials are currently studying tiragolumab for different cancer types and stages:

  • A trial combining tiragolumab with radiation and chemotherapy before surgery in patients with locally advanced esophageal cancer[1]
  • Studies using tiragolumab with atezolizumab before, during, or after other cancer treatments like chemotherapy and radiation for lung cancer[2][3]
  • A trial of tiragolumab plus atezolizumab as an additional treatment after surgery for patients with high-risk solid tumors[4]
  • Research on tiragolumab with atezolizumab for metastatic cervical cancer[5]

Potential Side Effects

As tiragolumab is still being studied in clinical trials, all of its potential side effects are not yet known. However, common side effects of immunotherapy drugs can include:

  • Fatigue
  • Skin rash
  • Diarrhea
  • Nausea
  • Fever

More serious immune-related side effects are possible but less common. Patients in clinical trials are closely monitored for any adverse reactions[2][5].

Frequently Asked Questions

Is tiragolumab approved for use yet?

No, tiragolumab is still an investigational drug being studied in clinical trials. It is not yet approved by regulatory agencies for general use.

How is tiragolumab given to patients?

Tiragolumab is typically given as an intravenous (IV) infusion every 3 or 4 weeks, often along with other cancer treatments[5].

Who might be eligible for a clinical trial with tiragolumab?

Eligibility varies by trial, but generally includes patients with specific cancer types, stages, and prior treatments. Some trials focus on cancers with certain genetic features. Patients should discuss clinical trial options with their oncologist[4].

Summary

AspectDetails
Drug TypeImmunotherapy (anti-TIGIT antibody)
MechanismBlocks TIGIT protein to activate immune cells against cancer
Conditions StudiedNSCLC, esophageal cancer, cervical cancer, other solid tumors
AdministrationIntravenous infusion every 3-4 weeks
Current StatusIn clinical trials, not yet approved
Common CombinationOften used with atezolizumab (Tecentriq)

Glossary

  • Immunotherapy – A type of cancer treatment that helps the body’s immune system fight cancer
  • TIGIT – A protein found on immune cells that can inhibit their ability to fight cancer
  • PD-L1 – Another protein that cancer cells can use to evade the immune system
  • Non-small cell lung cancer (NSCLC) – The most common type of lung cancer
  • Esophageal squamous cell carcinoma – A cancer that forms in the cells lining the esophagus
  • Metastatic – Cancer that has spread from its original location to other parts of the body

Trial Sources

  • [1]: https://clinicaltrials.gov/study/NCT05743504
  • [2]: https://clinicaltrials.gov/study/NCT05798663
  • [3]: https://clinicaltrials.gov/study/NCT05034055
  • [4]: https://clinicaltrials.gov/study/NCT06331598
  • [5]: https://clinicaltrials.gov/study/NCT04300647
Aspect Details
Drug Name Tiragolumab
Drug Type Immunotherapy (anti-TIGIT antibody)
Common Combination Often used with atezolizumab (anti-PD-L1 antibody)
Cancer Types Studied NSCLC, cervical cancer, head and neck cancer, melanoma, other solid tumors
Administration Intravenous infusion, typically 600 mg every 3 weeks
Trial Phases Phase I, II, and III studies ongoing
Key Outcomes Measured Progression-free survival, overall survival, objective response rate, pathological complete response
Potential Benefits Enhanced immune response against cancer, potential for improved outcomes in combination therapy
Safety Considerations Side effects being monitored, including immune-related reactions

FAQ

  • What is tiragolumab and how does it work? Tiragolumab is an immunotherapy drug that targets a protein called TIGIT. It works by helping the immune system recognize and attack cancer cells more effectively. Tiragolumab is often used in combination with other immunotherapy drugs to potentially enhance the body's immune response against cancer.
  • What types of cancer is tiragolumab being studied for? Tiragolumab is being investigated in clinical trials for various types of cancer, including non-small cell lung cancer (NSCLC), cervical cancer, head and neck cancer, melanoma, and other solid tumors. It's being studied both as a standalone treatment and in combination with other drugs.
  • How is tiragolumab administered to patients? In most clinical trials, tiragolumab is given as an intravenous (IV) infusion. The typical dose is 600 mg, administered every 3 weeks. However, the exact dosage and schedule may vary depending on the specific trial and treatment plan.
  • What are the potential side effects of tiragolumab? As with any medication, tiragolumab may cause side effects. Common side effects observed in clinical trials include fatigue, nausea, and immune-related reactions. However, the full range of potential side effects is still being studied. Patients in clinical trials are closely monitored for any adverse reactions.
  • How can I find out if I'm eligible for a clinical trial involving tiragolumab? Eligibility for clinical trials involving tiragolumab depends on various factors, including the type and stage of cancer, previous treatments, and overall health. If you're interested in participating in a clinical trial, discuss this option with your oncologist. They can help determine if you meet the criteria for any ongoing trials and guide you through the process.

Ongoing Clinical Trials on Tiragolumab

  • Study on the Effectiveness and Safety of TPST-1120 and Drug Combination for Patients with Advanced Liver Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Continued Cancer Treatment Study with Abiraterone, Ipatasertib, Tiragolumab, and Drug Combination for Patients from Previous Genentech/Roche Trials

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Greece Poland

  • Study on Immunotherapy with Atezolizumab, Tiragolumab, and Ipilimumab for Patients with Advanced Triple Negative Breast Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Non-Small Cell Lung Cancer (NSCLC)

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Greece Italy +3

  • Study of Atezolizumab and Tiragolumab for Patients with Recurrent or Metastatic PD-L1 Positive Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Greece Hungary Poland Spain

  • Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Italy Poland

  • Study on Atezolizumab and Tiragolumab for Patients with Head and Neck Cancer, Metastatic Melanoma, and Other Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness and Safety of Immunotherapy with Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Tiragolumab and Atezolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Not Had Chemotherapy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

Glossary

  • Tiragolumab: An immunotherapy drug that targets the TIGIT protein, designed to enhance the immune system's ability to fight cancer cells.
  • Atezolizumab: An immunotherapy drug that targets the PD-L1 protein, often used in combination with tiragolumab in clinical trials.
  • TIGIT: T-cell immunoreceptor with immunoglobulin and ITIM domain, a protein targeted by tiragolumab to boost immune response against cancer.
  • PD-L1: Programmed death-ligand 1, a protein targeted by some immunotherapy drugs to help the immune system recognize and attack cancer cells.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • Clinical trial: A research study that tests how well new medical approaches work in people.
  • NSCLC: Non-small cell lung cancer, a common type of lung cancer being studied in tiragolumab trials.
  • Intravenous (IV) infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Neoadjuvant therapy: Treatment given before the main treatment, often to shrink a tumor before surgery.
  • Adjuvant therapy: Additional treatment given after the primary treatment to lower the risk of cancer coming back.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Pathological complete response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.